PresseBox
Pressemitteilung BoxID: 699415 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • http://www.4sc.de
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC AG issues second tranche of convertible notes with a nominal amount of EUR 500,000 to Yorkville

(PresseBox) (Planegg-Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC) today announced that it successfully completed the issuance of convertible notes with a nominal amount of EUR 500,000.00. 4SC will use the proceeds for the further preparation of a planned clinical Phase II study with its cancer compound resminostat in the liver cancer indication.

These convertible notes constitute the second tranche of a total issuance of up to EUR 15 million guaranteed by an agreement between YA Global Master SPV Ltd. ("Yorkville") and the Company, as announced in an ad hoc release dated 12 February 2014. Prior to this, a first tranche of convertible notes issued in March 2014 of nominally EUR 500,000.00 was completely converted into shares. Following the successful conversion of previously issued tranches, 4SC's Management will decide independently on a case-by-case basis whether additional tranches will be issued.

Excluding the pre-emptive rights of existing shareholders, the convertible notes will be issued exclusively to Yorkville at a subscription price corresponding to 95% of the nominal amount. The notes carry no interest, have a term of nine month and may be converted into shares of 4SC by the holder of the notes at any time. The conversion price equals the volume weighted average trading price of 4SC shares during a five-day period prior to the time of conversion, less a 5% discount, but it cannot be lower than EUR 1.00.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.